Paclitaxel and cisplatin sensitivity of ovarian carcinoma cell lines tested with the 96-well plate clonogenic assay.

摘要: Platinum based chemotherapy is the cornerstone of treatment in advanced ovarian carcinoma. Paclitaxel, an unique antimicrotubule agent has shown significant clinical activity cisplatin-resistant tumours, indicating a lack cross-resistance. To compare vitro sensitivity carcinoma to cisplatin and paclitaxel, we tested 7 cell lines with 96-well plate clonogenic assay. Chemosensitivity was expressed as IC50 value i.e. drug concentration causing 50% inhibition survival. values were obtained from dose-response curves after fitting data linear quadratic equation. The for paclitacel 0.4-3.4 nM, showing 8.5-fold difference between various lines. 0.1-0.45 ug ml-1 only 4.5-fold difference. This variance clearly smaller than 25-fold observed same method endometrial (Rantanen et al, Br J Cancer 69: 482-86, 1994). In accordance findings, no cross-resistance or correlation paclitaxel could be demonstrated.